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Vasopressin and its analogues in treatment of cardiac arrest 
 
Introduction: Recent guidelines for cardiopulmonary resuscitation (CPR) recommend use 
of drugs as an integral part of treatment. Vasoactive drugs have been used in resuscitation 
to increase myocardial and cerebral perfusion during chest compressions. Resuscitation 
research is trying to find alternative vasopressors to adrenaline, for which the long-term 
survival benefit has not been proven. Successful use of terlipressin in cardiac arrest (CA) 
was documented in small studies in children and some rare case reports. Terlipressin has 
never been tested in CA of cardiac aetiology in any clinical or experimental study. 
Objectives: We aimed to evaluate the role of catecholamines and non-adrenergic 
vasopressors, vasopressin and terlipressin, during CPR based on review of selected trials.  
Introduction of a standardized experimental porcine model of ventricular fibrillation (VF) 
was done for research of therapeutic interventions during CPR. We aimed to evaluate the 
effects of terlipressin with adrenaline on perfusion of vital organs during prolonged CPR 
compared to placebo with adrenaline. We tested our hypothesis that terlipressin, if given  
simultaneously with the first dose of epinephrine during CPR for VF, increases CorPP 
(coronary perfusion pressure) or CPP (cerebral perfusion pressure). 
Material and methods: Fourteen domestic pigs were randomly assigned into group ADR 
(placebo + adrenaline; n = 7) and TER (terlipressin + adrenaline; n = 7). VF was induced 
using an intra-cardiac pacing lead. After 5 min of untreated CA, compression-only 
resuscitation was applied for 10 min, followed by advanced life support. Terlipressin  
in a single-dose of 30 µg kg-1 was added to the first dose of adrenaline (30 µg kg-1) in 
group TER, while placebo was given in group ADR. Coronary (CorPP) and cerebral (CPP) 
perfusion pressures were calculated from right atrial, aortic and intracerebral pressures. 
Data were analyzed using repeated ANOVA and Fisher´s protected LSD post hoc test. 
Results: Administration of terlipressin with adrenaline was effective to maintain CorPP 
higher than 10 mmHg for 17.7 min longer than adrenaline alone (P = 0.003). CorPP (mean 
± SD) measured at 35,  45, and 55 min after the onset of VF was 12.2 ± 4.0, 11.0 ± 6.2, and 
9.6 ± 4.5 mmHg in group TER; and 5.8 ± 3.8, 0.6 ± 4.9, and -1.0 ± 4.5 mmHg in group 
ADR (P = 0.03, < 0.001, and < 0.001). CPP measured at the same times was 23.0 ± 7.2, 
20.4 ±6.9, and 23.1 ± 6.7 mmHg in group TER; and 13.3 ± 6.5, 6.2 ± 5.3, and 5.6 ± 6.5 
mmHg in group ADR (P = 0.01, < 0.001, and < 0.001). A trend towards extended duration 
of VF was observed after administration of terlipressin with adrenaline. 
Conclusion: The porcine model of CA has been successfully introduced. A consecutive 
study performed on this model of VF confirmed our hypothesis that terlipressin, when 
given with the first dose of adrenaline during CPR, increases CorPP and CPP compared to 
adrenaline with placebo. However, based on the conclusions of clinical and experimental 
studies, routine use of vasopressin or terlipressin in humans still cannot be recommended. 
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